首页> 美国卫生研究院文献>Molecules >Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 123-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design Synthesis and Biological Evaluation
【2h】

Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 123-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design Synthesis and Biological Evaluation

机译:创新的三步微波促进合成N-炔丙基四氢喹啉和123-三唑衍生物作为潜在因子Xa(FXa)抑制剂:药物设计合成和生物学评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The coagulation cascade is the process of the conversion of soluble fibrinogen to insoluble fibrin that terminates in production of a clot. Factor Xa (FXa) is a serine protease involved in the blood coagulation cascade. Moreover, FXa plays a vital role in the enzymatic sequence which ends with the thrombus production. Thrombosis is a common causal pathology for three widespread cardiovascular syndromes: acute coronary syndrome (ACS), venous thromboembolism (VTE), and strokes. In this research a series of -propargyltetrahydroquinoline and 1,2,3-triazole derivatives as a potential factor Xa (FXa) inhibitor were designed, synthesized, and evaluated for their FXa inhibitor activity, cytotoxicity activity and coagulation parameters. Rational design for the desired novel molecules was performed through protein-ligand complexes selection and ligand clustering. The microwave-assisted synthetic strategy of selected compounds was carried out by using Ullmann-Goldberg, -propargylation, Mannich addition, Friedel-Crafts, and 1,3-dipolar cycloaddition type reactions under microwave irradiation. The microwave methodology proved to be an efficient way to obtain all novel compounds in high yields (73–93%). Furthermore, a thermochemical analysis, optimization and reactivity indexes such as electronic chemical potential (µ), chemical hardness (η), and electrophilicity (ω) were performed to understand the relationship between the structure and the energetic behavior of all the series. Then, in vitro analysis showed that compounds , – , and exhibited inhibitory activity against FXa and the corresponding half maximal inhibitory concentration (IC ) values were calculated. Next, a cell viability assay in HEK293 and HepG2 cell lines, and coagulation parameters (anti FXa, Prothrombin time (PT), activated Partial Thromboplastin Time (aPTT)) of the most active novel molecules were performed to determine the corresponding cytotoxicity and possible action on clotting pathways. The obtained results suggest that compounds and inhibited FXa targeting through coagulation factors in the intrinsic and extrinsic pathways. However, compound may target coagulation FXa mainly by the extrinsic and common pathway. Interestingly, the most active compounds in relation to the inhibition activity against FXa and coagulation parameters did not show toxicity at the performed coagulation assay concentrations. Finally, docking studies confirmed the preferential binding mode of -propargyltetrahydroquinoline and 1,2,3-triazole derivatives inside the active site of FXa.
机译:凝血级联反应是将可溶性纤维蛋白原转化为不溶性纤维蛋白的过程,该过程终止于血块的产生。 Xa因子(FXa)是一种参与血液凝固级联的丝氨酸蛋白酶。此外,FXa在酶促序列中起着至关重要的作用,酶促序列以血栓的产生结束。血栓形成是三种广泛的心血管综合征的常见病因病理:急性冠脉综合征(ACS),静脉血栓栓塞(VTE)和中风。在这项研究中,设计,合成了一系列-炔丙基四氢喹啉和1,2,3-三唑衍生物作为潜在的因子Xa(FXa)抑制剂,并评估了它们的FXa抑制剂活性,细胞毒性活性和凝血参数。通过蛋白质-配体复合物的选择和配体的聚类,对所需的新型分子进行了合理的设计。所选化合物的微波辅助合成策略是通过在微波辐射下使用Ullmann-Goldberg,-炔丙基化,Mannich加成,Friedel-Crafts和1,3-偶极环加成型反应进行的。事实证明,微波方法是一种高效获得所有新型化合物(73%至93%)的有效方法。此外,进行了热化学分析,优化和反应性指标,例如电子化学势(µ),化学硬度(η)和亲电性(ω),以了解所有系列的结构与高能行为之间的关系。然后,体外分析表明,化合物,和对FXa表现出抑制活性,并计算出相应的半数最大抑制浓度(IC)值。接下来,在最活跃的新分子中进行HEK293和HepG2细胞系中的细胞活力测定以及凝血参数(抗FXa,凝血酶原时间(PT),活化的部分凝血活酶时间(aPTT)),以确定相应的细胞毒性和可能的​​作用在凝血途径上。获得的结果表明,化合物和内源性和外源性途径中的凝血因子均可通过凝血因子抑制。但是,化合物可能主要通过外部途径和共同途径靶向凝血FXa。有趣的是,与针对FXa的抑制活性和凝血参数有关的最具活性的化合物在所执行的凝血试验浓度下未显示毒性。最后,对接研究证实了FXa活性位点内-炔丙基四氢喹啉和1,2,3-三唑衍生物的优先结合模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号